单位：[1]Humanity and Health Clinical Trial Center, Humanity and Health Medical Group, Hong Kong SAR, China [2]The Fifth Medical Center of Chinese, PLA General Hospital, Beijing 100039, China [3]Hepatitis Center and Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, No. 100, Tz‑You 1st Rd, Chinese Taipei, Kaohsiung, Taiwan [4]Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR, China [5]St Vincent’s Hospital, Melbourne, VIC, Australia [6]Department of Hepatology, Nork Clinical Hospital of Infectious Diseases, Yerevan, Armenia [7]Department of Infectious Diseases, Institute of Hepatology, Nanfang Hospital, Southern Medical University, Guangzhou, China [8]Department of Medicine, NKC Institute of Gastroenterology and Hepatology, Songklanagarind Hospital, Prince of Songkla University, Hat Yai, Thailand [9]Liver Research Center, Beijing Friendship Hospital, Beijing, China 临床科室国家中心肝病分中心首都医科大学附属北京友谊医院[10]Genome Medical Science Project, National Center for Global Health and Medicine, Ichikawa, Japan [11]Faculty of Health Science, Macau University, Macau SAR, China [12]Department of Liver Diseases, Fifth Medical Center of Chinese, PLA General Hospital, Beijing, China [13]Research Center for Liver Transplantation, Fifth Medical Center of Chinese PLA General Hospital, Beijing, China [14]Department of Infectious Diseases, Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia [15]Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan [16]Department of Medicine, United Christian Hospital, Hong Kong SAR, China [17]Department of Clinical Oncology, State Key Laboratory of South China, Chinese University of Hong Kong, Hong Kong SAR, China [18]Division of Nephrology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan [19]Department of Medicine, Aga Khan University and Hospital, Stadium Road, Karachi 74800, Pakistan [20]Department of Gastroenterology, Ankara University School of Medicine, Ankara, Turkey [21]Liver Transplantation Team, Ciptomangunkusumo Hospital, Jakarta, Indonesia [22]Department of Medicine, Cardinal Santos Medical Center, Mandaluyong, Metro, Manila, Philippines [23]Department of Hepatopancreatobiliary and Transplant Surgery, Singapore General Hospital, Singapore, Singapore [24]Center for Liver Cancer, Research Institute and Hospital, National Cancer Center, Goyang, Korea [25]AW Morrow Gastroenterology and Liver Centre, Royal Prince Alfred Hospital, Sydney, Australia [26]Department of Medicine, University Malaya Medical Centre, Kuala Lumpur, Malaysia [27]Yangon Gastroenterology and Liver Centre, Yangon, Myanmar [28]Division of Gastroenterology, Department of Medicine, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand [29]Department of Hepatology, Institute of Liver and Biliary Sciences, New Delhi, India [30]Yamanashi Prefectural Central Hospital, 1‑1‑1 Fujimi, Kofu‑shi, Yamanashi 400‑8506, Japan [31]The University of Tokyo, 7‑3‑1 Hongo, Bunkyo‑ku, Tokyo 113‑8655, Japan
Background & Aim Hepatitis B reactivation related to the use of immunosuppressive therapy remains a major cause of liver-related morbidity and mortality in hepatitis B endemic Asia-Pacific region. This clinical practice guidelines aim to assist clinicians in all disciplines involved in the use of immunosuppressive therapy to effectively prevent and manage hepatitis B reactivation. Methods All publications related to hepatitis B reactivation with the use of immunosuppressive therapy since 1975 were reviewed. Advice from key opinion leaders in member countries/administrative regions of Asian-Pacific Association for the study of the liver was collected and synchronized. Immunosuppressive therapy was risk-stratified according to its reported rate of hepatitis B reactivation. Recommendations We recommend the necessity to screen all patients for hepatitis B prior to the initiation of immunosuppressive therapy and to administer pre-emptive nucleos(t)ide analogues to those patients with a substantial risk of hepatitis and acute-on-chronic liver failure due to hepatitis B reactivation.
第一作者单位：[1]Humanity and Health Clinical Trial Center, Humanity and Health Medical Group, Hong Kong SAR, China [2]The Fifth Medical Center of Chinese, PLA General Hospital, Beijing 100039, China
通讯作者：
通讯机构：[1]Humanity and Health Clinical Trial Center, Humanity and Health Medical Group, Hong Kong SAR, China [2]The Fifth Medical Center of Chinese, PLA General Hospital, Beijing 100039, China
推荐引用方式(GB/T 7714)：
George Lau,Ming‑Lung Yu,Grace Wong,et al.APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy[J].HEPATOLOGY INTERNATIONAL.2021,15(5):1031-1048.doi:10.1007/s12072-021-10239-x.
APA：
George Lau,Ming‑Lung Yu,Grace Wong,Alexander Thompson,Hasmik Ghazinian...&Masao Omata.(2021).APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy.HEPATOLOGY INTERNATIONAL,15,(5)
MLA：
George Lau,et al."APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy".HEPATOLOGY INTERNATIONAL 15..5(2021):1031-1048
医学